New pill JAB-3312 tested in patients with advanced cancers

NCT ID NCT04045496

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug might slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JAB-3312 (an oral drug taken as capsules)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 40 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • HealthONE Clinic Services Oncology-Hematology

    Denver, Colorado, 80202, United States

  • Tennessee Oncology, PLLC

    Nashville, Tennessee, 37203, United States

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Washington University School of Medicine

    Seattle, Washington, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.